The CXCR4 Antagonist, AMD3100, Reverses Mesenchymal Stem Cell-Mediated Drug Resistance in Relapsed/Refractory Acute Lymphoblastic Leukemia.

Onco Targets Ther · 2020 · PMC7352451 · PMID 32753894

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Curiously, we also found that the surface expression of CXCR4 showed a decreasing trend when ALL cells were co-cultured with UCMSCs while the cell viability improved.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.